Regulatory decisions

Approvals and other regulatory decisions, in the order we post them.

Show news for

November 2026

  1. Durvalumab (Imfinzi) + enfortumab vedotin-ejfv approved by the US FDA for muscle-invasive bladder cancer (MIBC)

    Genitourinary. November 15, 2026.

October 2026

  1. FDA approves talazoparib plus enzalutamide in prostate cancer with HRR gene mutations

    Genitourinary. FDA. October 26, 2026.

  2. FDA NEWS | AZUR 1 Update in Rectal Cancer

    Gastrointestinal. FDA. October 19, 2026.

  3. Atezolizumab approved with fluoropyrimidine + oxaliplatin for adjuvant Stage III dMMR Colon Cancer (adults & peds ≥2 yrs).

    Gastrointestinal. FDA. October 12, 2026.

  4. FDA NEWS: HER2CLIMB-05 Update

    Breast. FDA. October 7, 2026.